Recommendations for moderate alcohol consumption remain controversial, particularly in type 2 diabetes mellitus (T2DM). Long-term randomized, controlled trials (RCTs) are lacking.
T he risk-benefit balance of moderate alcohol consumption in persons with diabetes is controversial (1, 2) . Epidemiologic studies suggest that the incidence of type 2 diabetes mellitus (T2DM) is reduced among moderate alcohol drinkers (3) (4) (5) (6) (7) . Among healthy persons (8, 9) and diabetic patients (10 -12) , moderate alcohol consumption is linked to lower cardiovascular and total mortality rates. Yet, whether to recommend initiation of moderate alcohol consumption to patients with T2DM is questionable. The American Diabetes Association (13) leaves moderate alcohol consumption to personal preference. The American Heart Association (14) recommends that alcohol use be discussed by the physician and patient, given the lack of longterm trials that support causal cardioprotective effects (15) .
A recent systematic review summarized short-term clinical trials (16) that mostly involved healthy participants and suggested that moderate alcohol consumption is associated with favorable patterns of biomarkers of cardiovascular risk. The effect of moderate alcohol consumption on blood pressure (BP) (17) and adiposity remains controversial (18, 19) .
Some studies (20 -23) suggest similar beneficial associations for different alcoholic beverages and implicate ethanol as the primary mediator. In contrast, other studies (24 -27) propose that red wine may induce superior benefits; whether red wine confers any advantage over white wine is unclear.
After a 3-month feasibility trial (28) in 109 patients with T2DM, we performed the 2-year CASCADE (CArdiovaSCulAr Diabetes & Ethanol) trial among 224 diabetic patients. We hypothesized that initiating moderate wine consumption would improve cardiometabolic risk mainly because of the ethanol component. Therefore, we predicted similar effects of red and white wine. Because of genetic variability in alcohol metabolism, we further hypothesized that the effects of wine on the metabolic variables would vary by ADH1B (rs1229984) genotype.
METHODS

Design Overview
The 2-year CASCADE trial involved alcoholabstaining diabetic participants who were randomly assigned in a parallel design (1:1:1) to mineral water, white wine, or red wine (150 mL at dinnertime). Recruitment of participants began in November 2009. Participants who provided informed consent were weighed and measured at baseline and were randomly assigned to a single-phase, 2-year intervention (June 2010 to May 2012). The protocol did not change after trial commencement (earlier modifications are detailed in Appendix Figure 1 and the Appendix, available at www .annals.org). Further, CASCADE was conducted at 2 centers: Ben-Gurion University of the Negev-Soroka Medical Center (BGU-SMC) and Nuclear Research Center Negev (NRCN) in Israel. The study was approved and monitored by the human subjects committees of SMC and BGU, which also cover the NRCN. No financial compensation was provided to participants.
Setting and Participants
During recruitment, we intentionally avoided any emphasis on the alcohol component to correctly identify alcohol abstainers. Candidates were screened by a physician for eligibility. We included men and women aged 40 to 75 years with T2DM diagnosed according to the American Diabetes Association criteria (29). Exclusion criteria were as follows: more than 1 alcoholic drink per week; personal or family history of addiction, smoking, stroke, or myocardial infarction; major surgery within the past 3 months; using more than 2 insulin injections per day or an insulin pump; triglyceride level greater than 4.52 mmol/L (400 mg/dL), hemoglobin A 1c (HbA 1c ) level less than 6.4% or 10% or more; women with first-degree relatives with breast cancer; or pregnant women.
Randomization and Intervention
We performed the randomization (detailed in the Appendix) within strata of patients by recruitment site and planned substudies; we used the PROC PLAN procedure in SAS software, version 9.2 (SAS Institute). At NRCN, participants were randomly assigned to receive water or red wine (1:1 ratio). At BGU-SMC, participants in additional substudies were randomly assigned to water or red wine (1:1 ratio) and the remaining participants to water, red wine, or white wine (1:1:3 ratio). The participants were instructed to consume 150 mL (5 ounces) of the randomly assigned beverage with dinner by using a standard 150 mL measuring glass we provided. The randomized beverages were dry red wine (from Golan Heights Winery; 16.9 g of ethanol [14.2% by volume], with 270.1 mg of gallic acid equivalent of total phenols; 120 kcal/150 mL), dry white wine (from Golan Heights Winery; 15.8 g of ethanol [13.3% by volume], with 38.5 mg of gallic acid equivalent of total phenols; 111 kcal/150 mL), or mineral water (from Mey Eden). The red wine had 7-fold higher levels of total phenols and between 4-to 13-fold higher levels of the specific resveratrol group compounds than the white wine. We provided the beverages at no charge for 2 years (mineral water, 18.9 L/mo; white wine, 750 mL/mo [6 bottles]; or red wine, 325 mL/mo [14 bottles]). Patients assigned to consume wine were instructed to initiate drinking gradually over the first month and avoid driving after drinking. The participants were asked to return the empty bottles at each visit to monitor use.
Mediterranean Dietary Guidelines
In an attempt to achieve a comparable healthy diet and provide an incentive to participate, we provided all participants with guidelines to follow a Mediterranean diet as per our previous 2-year DIRECT (Dietary Inter-
EDITORS' NOTES Context
The long-term benefits and risks of moderate alcohol intake among patients with type 2 diabetes mellitus (T2DM) are unclear.
Contribution
Alcohol-abstaining patients with T2DM were randomly assigned to 150 mL (5 ounces) of red wine, white wine, or mineral water with dinner for 2 years. Primary study outcomes included lipid and glycemic control measures.
Caution
The trial did not include a grape juice control group.
Implication
Moderate alcohol intake, particularly red wine, among patients with T2DM was associated with decreased cardiometabolic risks and no significant adverse events. Genetic typing for alcohol dehydrogenase may identify patients who may benefit clinically from moderate alcohol consumption. (31) , other lipid and glycemic control biomarkers, genetic interaction and safety variables (specific symptoms, medication use, and liver function tests), and quality-oflife indicators. Blood samples were obtained at 0, 6, and 24 months at 8 a.m. after an 8-hour fast; stored at Ϫ80°C; and analyzed at laboratories in Leipzig, Germany, for biomarkers of glycemic control, lipid levels, and liver function (listed in Table 1 ; assay methods are described in the Appendix). We calculated the HOMA-IR score according to the following equation (32) : insulin (U/mL) × fasting glucose (mmol/L) ÷ 22.5. Participants (33) were weighed without shoes to the nearest 0.1 kg. Waist circumference was measured halfway between the last rib and the iliac crest. Two BP measurements were recorded after resting using an automatic BP monitor (Datascope Accutorr 4 [Datascope]).
ORIGINAL RESEARCH
Genetic Analysis of Alcohol Dehydrogenase
Genotyping of ADH1B*1 and ADH1B*2 (rs1229984 [www.snpedia.com/index.php/Rs1229984]) (34) was done on a 7300 Real-Time Polymerase Chain Reaction system (Applied Biosystems) using AccuStart Genotyping ToughMix, ROX (Biosearch Technologies), using blood samples from month 6.
Electronic Questionnaires
At 0, 6, and 24 months, participants completed validated (35, 36) electronic questionnaires (30) , which collected data on demographics, lifestyle patterns, specific medications and symptoms, and quality of life (Appendix) (28) . We assessed adherence to the beverage assignment by tracking the returned bottles and having participants complete a specific questionnaire about all alcohol intake within or outside of the protocol. Participants also ranked their degree of adherence to the assigned beverages using a scale of 0% to 100%.
Statistical Analysis
Our primary end points were lipid profile and glycemic control biomarkers. We conducted intention-totreat analyses, which included all 224 randomly assigned participants; further, we performed the longitudinal analysis (population-averaged generalized estimating equation models) using all available data through the most recent value, with multiple imputation for missing data at later time points. We analyzed all of the data using raw values without transformation. We calculated generalized estimating equation models with exchangeable correlation structure to account for within-subject correlations and Huber-White robust errors (using the "robust" option to the xtgee command ORIGINAL RESEARCH The main results present the changes from baseline in the wine groups compared with the change from baseline in the water group and the corresponding 95% CIs. We did a sensitivity analysis to compare participants who dropped out with those who completed the study; we also analyzed only participants who completed the study. We assessed the changes in sex-specific criteria values of the metabolic syndrome (31) over 24 months. We evaluated the ADH1B polymorphism for HardyWeinberg equilibrium and tested its effect on biomarker levels. We calculated mean changes in biomarkers within each of the 3 ADH1B genotypes for the combined red and white wine groups and the water group, and we tested for interaction between genotype and wine or water groups. For the analysis involving the glycemic variables, BP, and lipid and liver function biomarkers, we pooled data from carriers of either 1 or 2 wild-type alleles (CC and CT) and compared the data with participants who were homozygous for the TT (rs1229984) allele based on the biological effect and to enhance statistical power.
On the basis of the results of our pilot study (28) , which compared the effects of wine with nonalcoholic beer on glycemic control, we did not perform a formal power calculation for this study. All P values were 2-sided. We used Stata software, version 12, and SPSS software, version 19 (IBM), for statistical analyses.
Role of the Funding Source
The European Foundation for the Study of Diabetes provided funding for the study. Beverages were provided by Mey Eden and Golan Heights Winery. These sources were not involved in the design of the study, collection of data, statistical analysis, manuscript preparation or interpretation, or decisions about submission for publication.
RESULTS
Baseline Characteristics
Of the 224 randomly assigned participants, 94% and 87% completed the 12-and 24-month assessments, respectively (mineral water, 94%; white wine, 77%; red wine, 88%; P = 0.007 among groups) (Appendix Figure 1 ). Baseline characteristics were distributed similarly across the groups ( Table 1) . The participants (aged 59 years; 69% men; HbA 1c level, 6.9%) had an average of 3.1 of 5 criteria of the metabolic syndrome. Most participants were receiving medications for diabetes, hypertension, and hypercholesterolemia. Baseline alcohol intake was 2.3 grams per day (approximately 1 drink per week). The BGU-SMC participants (Appendix Table 1 , available at www.annals.org) were slightly older, had a smaller proportion of men, and had lower total cholesterol-HDL-C ratio than NRCN participants. All other baseline biomarkers and ethanol consumption were similar.
Adherence
During the trial, participants in the wine groups increased their intake of the specifically assigned wines (approximately 80% consumed daily), and the mineral water group participants remained alcohol abstainers. Beverage adherence, as reflected in the self-reported scale (1% to 100%), was 82%, 85%, and 80% at 6 months and 87%, 84%, and 84% at 2 years for mineral water, white wine, and red wine groups, respectively (Appendix Figure 2 , available at www.annals.org). The P values represent the comparison of 2-y differences in the red wine group versus the water group. Variables are mean changes; bars indicate 95% CIs, and the between-group analyses for differences are for 2 y. At 6 mo, the participants who completed the study were as follows: mineral water, 81; white wine, 62; red wine, 73. After 2 y, 30 participants dropped out (incomplete set of observations). The participants who completed the study were as follows: mineral water, 78; white wine, 52; red wine, 64. To convert HDL-C values to mmol/L, multiply by 0.0259. To convert apolipoprotein(a) 1 values to g/L, multiply by 0.01. HDL-C = high-density lipoprotein cholesterol. 
Two-Year Changes
All of the findings are presented as the change from baseline in the wine groups compared with the change from baseline in the water group.
Primary Outcomes
After 2 years ( Figure 1 and Table 2 ), HDL-C levels significantly increased in the red wine group by 0.05 mmol/L (2.0 mg/dL) (95% CI, 0.04 to 0.06 mmol/L [1.6 to 2.2 mg/dL]; P < 0.001) compared with the water group. Changes in apolipoprotein(a) 1 levels in the red wine group had a similar pattern (0.03 g/L [CI, 0 to 0.06 g/L]; P = 0.050) compared with the water group. Beneficial 2-year changes include that the total cholesterol-HDL-C ratio further decreased in the red wine group by 0.27 (CI, Ϫ0.52 to Ϫ0.01; P = 0.039) compared with the water group. The corresponding lipid changes in the white wine group were not significantly different from those in the water group.
Although both wines tended to improve some glucose metabolism components after 2 years, only white wine significantly decreased fasting plasma glucose level by 1.0 mmol/L (Ϫ17.2 mg/dL) (CI, Ϫ1.60 to Ϫ0.3 mmol/L [Ϫ28.9 to Ϫ5.5 mg/dL]; P = 0.004) and HOMA-IR score by 1.2 (CI, Ϫ2.1 to Ϫ0.2; P = 0.019) compared with the water group (Figure 2) . Primary outcomes did not vary across the recruitment sites (Appendix Figure 3 , available at www.annals.org). The results did not materially differ among participants who completed the trial compared with the entire group (Appendix Figure 1) .
Secondary Outcomes
The apolipoprotein(b) 100 -apolipoprotein(a) 1 ratio decreased only in the red wine group by 0.03 (CI, Ϫ0.06 to 0.00; P = 0.058) compared with the water group. Changes in triglyceride levels were more favorable in the white wine group (Ϫ0.09 mmol/L [Ϫ7. 
Adiposity and BP
All 3 groups had modest and similar reductions in waist circumference (mean, Ϫ1.48 cm) and body weight (mean, Ϫ1.4 kg) from baseline. After 2 years of intervention, we found no significant differences in BP among the 3 groups (Table 2) . 1 * After 2 y of the intervention, 30 participants dropped out and had incomplete sets of observations. The following participants completed the intervention: mineral water (n = 78), white wine (n = 52), and red wine (n = 64). † Between-group analyses for 2-y differences. 
ORIGINAL RESEARCH
Genetic Interaction of ADH1B and Wine
Of the 203 participants with available DNA samples, 35.6% were homozygous for the wild-type C allele ADH1B*1 (CC: "slow ethanol metabolism"), 21.3% were homozygous for ADH1B*2 (Arg48His; rs1229984; TT: "fast ethanol metabolism"), and 43.1% were heterozygous (CT), which was consistent with the Hardy-Weinberg equilibrium. We analyzed 2-year genetic data from 173 participants who had DNA samples and had completed the trial. As expected in the water group, changes in biomarkers did not differ across genetic ADH1B variants. When the red and white wine groups were combined (Figure 3) , however, the improvements in glycemic control were mostly achieved among carriers of ADH1B*1. These carriers had favorable significant changes compared with carriers of ADH1B*2 homozygotes; FPG level was Ϫ0.21 mmol/L (Ϫ3.8 mg/dL) versus 0.82 mmol/L (14.8 mg/dL; P = 0.043), HOMA-IR score was Ϫ1.4 versus 0.3 (P = 0.012), and HbA 1c level was 0.1% versus 0.6% (P = 0.024). The test for interaction between genotype and wine or water had a P value of less than 0.05.
In contrast to the favorable effect of ADH1B*1 on glycemic control variables, we found a statistically significant improvement in BP only among the fast metabolizers; homozygotes for ADH1B*2 (TT; rs1229984) exhibited stronger BP-lowering effects of wine on diastolic (P = 0.006) and systolic (P = 0.059) BP compared with ADH1B*1 wild-type C allele carriers. The ADH1B During the trial, the participants had no material changes in energy intake (Ϫ36 kcal/d) or energy expenditure (0.78 metabolic equivalents/wk). However, all 3 groups improved their nutrition similarly as expected from the Mediterranean diet (Appendix Figure  4 , available at www.annals.org).
We saw no significant wine-related adverse events, symptoms (Appendix Table 2 , available at www.annals .org), or changes in quality of life, except that reported sleep quality was significantly improved in both wine groups compared with water (P = 0.040).
In all 3 groups, there was no material change in drug therapy according to the use of oral hypoglycemic agents; insulin; or antihypertensive, lipid-lowering, or antiplatelet agents (Appendix Figure 5 , available at www.annals.org).
No material changes were seen in liver function tests (alanine aminotransferase, aspartate aminotrans- The P values represent the comparison of 2-y differences in the white wine group versus the water group. Variables are mean change; bars indicate 95% CIs, and the between-group analyses for differences are for 2 y. At 6 mo, the participants who completed the study were as follows: mineral water, 81; white wine, 62; red wine, 73. After 2 y, 30 participants dropped out (incomplete set of observations). The participants who completed the study were as follows: mineral water, 78, white wine, 52; red wine, 64. To convert FPG values to mmol/L, multiply by 0.0555. FPG = fasting plasma glucose; HOMA-IR = homeostatic model assessment of insulin resistance. ferase, alkaline phosphatase, or bilirubin) in any of the 3 groups (Appendix Figure 6 , available at www.annals .org). The ADH1B polymorphism had no significant effect on changes in liver enzymes (Appendix Figure 7 , available at www.annals.org).
Overall Effect on the Metabolic Syndrome
Compared with water, only the red wine group had an overall further significant decrease in the number of variables of the metabolic syndrome by 0.34 (CI, Ϫ0.68 to Ϫ0.001; P = 0.049) ( Table 2 ) (Appendix Figure 8 , available at www.annals.org).
DISCUSSION
There are several clinical implications of this 2-year trial. First, among patients with well-controlled T2DM and a low risk for alcohol abuse, initiating moderate alcohol consumption in the context of a healthy diet is apparently safe and may modestly reduce cardiometabolic risk. Second, red wine may be somewhat superior in improving lipid variables, which indicates the potential synergy of moderate alcohol intake with specific nonalcoholic wine constituents. Third, differential effects on the glycemic control we saw were based on ADH1B genetic variants, which indicate that ethanol may play a role in the glycemic effects of the wine intervention. Finally, ADH1B variants may assist in identifying patients with T2DM for whom moderate wine consumption may be clinically beneficial.
The study has several limitations. First, study participants were not blinded to group assignment. Second, the gold standard for assessing insulin resistance is the hyperinsulinemic euglycemic clamp (37), but we used fasting insulin and glucose levels to estimate insulin resistance (32) . The HOMA-IR score, however, correlates reasonably well with results of clamp studies, including in diabetic patients (38) . In addition, change in HDL-C level may not necessarily correlate with HDL functionality (39) . Despite the known differences in pharmacokinetics of alcohol by sex (40), we provided similar alcohol doses for both sexes for safety and simplicity. Thus, a 2-glass-per-day regimen among men might have yielded larger changes. We relied on self-reported alcohol intake to assess adherence, but we also monitored use by reviewing returned empty bottles. Finally, we cannot dissect the contribution of nonalcoholic red wine constituents from their combined effect with ethanol.
Strengths of the study include its long duration, use of comprehensive measurements, and high percentage of participants who completed the 2-year follow-up. The nutritional education sessions and free mineral water supply to the control group allowed equal intensity of intervention and enabled assessment of winespecific effects within the setting of a Mediterranean diet. The CASCADE design benefited from initiating the intervention in a population that generally has low consumption of alcohol (41) and reducing the risk for abuse by including participants older than 40 years with low addictive risk. Finally, the consistent findings within the groups of glycemic, lipid, liver, BP, and anthropometric variables underscore the robustness of the results. The differences we saw between red and white wine contrast with our original hypothesis that the beneficial effects of wine are mediated predominantly by alcohol (16, 23) . Although our results suggest that the effect of wine on glycemic control was mainly driven by alcohol, a stronger effect of red wine was seen on lipid levels and overall variables of the metabolic syndrome. The provided wines were nearly equal in alcohol and caloric content; however, the levels of total phenols in red wine were 7 times higher. Whether red wine's phenolic compounds (mostly resveratrol and quercetin) (42) render it a uniquely cardioprotective alcoholic beverage is still debated (43) (44) (45) because the systemic bioavailability of polyphenols (46) is argued to be low. Differences between red and white wine should be further considered in this context.
The beneficial effect on lipid profile was manifested mostly by increased HDL-C (9.8% increase in the red wine group) and apolipoprotein(a) 1 levels. In a recent meta-analysis (16), 30 to 40 g of ethanol per day significantly increased HDL-C levels by 0.09 to 0.10 mmol/L (3.5 to 4 mg/dL) and apolipoprotein(a) 1 level by 0.1 g/L; further, triglyceride or low-density lipoprotein cholesterol levels were not affected during shortterm (up to 3 months) trials. An 8-week trial in 20 insulin-resistant participants with an alcohol intake of 30 g increased HDL-C levels (47) , but this did not occur in a 30-day trial in 18 diabetic patients (48) . The increased transport rate of apolipoprotein(a) 1 and apolipoprotein(a) 2 (49) , elevated lipoprotein lipase activity (50) , increased cellular cholesterol efflux and its esterification (51), and decreased cholesteryl ester transfer protein activity (52, 53) are some suggested mechanisms for wine's ability to increase HDL-C levels.
The improvement of glycemic control was revealed mainly by changes in FPG level and HOMA-IR score in the white wine group compared with the water group. When alcohol is administered on a short-term basis to diabetic patients, inhibited gluconeogenesis is compensated by increased glycogenolysis and leaves hepatic glucose output unaltered (54) . Our earlier 3-month pilot trial (28) showed that FPG level, but not HbA 1c or 2-hour postprandial glucose levels, was decreased by wine intervention. In CASCADE, although the hypoglycemic effect was similar within the first 6 months for both the red and white wine groups, white wine had a modest advantage over red wine after 2 years for FPG level; however, this could be a chance finding. The CASCADE participants had well-treated T2DM at baseline, with a satisfactory baseline mean HbA 1c level (6.9%). One may speculate that the effect of moderate wine consumption might manifest in decreased HbA 1c level only in patients whose metabolic levels are less well-controlled (55) .
Class 1 alcohol dehydrogenase contributes to approximately 70% of total hepatic ethanol-oxidizing capacity (56) , and a common polymorphism of the ADH1B gene, Arg48His (rs1229984), is associated with greatly enhanced enzymatic activity (56, 57) . The genealcohol and diabetes risk interaction is controversial in observational studies (58, 59) . We found that diabetic patients who were slow alcohol metabolizers had improved glycemic control by initiating moderate wine consumption, which suggests that alcohol may play a role in glucose metabolism. In contrast, diabetic patients who were fast ethanol metabolizers benefited the most from the wine-induced BP-lowering effect, which suggests a mediatory role for ethanol metabolites and potentially explains the inconsistent reports about BP effects on moderate alcohol intake (17). Our results are in accordance with a recent Mendelian randomization analysis of observation studies reporting that carriers of the ADH1B (rs1229984) had lower BP (2) .
Initiation of wine consumption did not alter the number of medications used and did not adversely affect liver function biomarkers or adiposity. The benefit of wine on sleep quality was in accordance with our previous wine trial (28) . To our knowledge, CASCADE is the first large, long-term RCT of alcohol, and the results suggest modest beneficial effects of initiating moderate wine consumption among alcohol-abstaining patients older than 40 years with T2DM. These benefits should be weighed against potential risks when translated into clinical practice.
The randomization was performed by the statisticians from BGU in SAS, version 9.2, using the procedure PROC PLAN.
Electronic Questionnaires
Participants completed electronic questionnaires (at 0, 6, and 24 months) to collect data on demographics, lifestyle patterns, specific medications and symptoms, and quality of life (28) . We assessed changes in quality of life by inquiring about the frequency of the following feelings: active, nervous, calm, energetic, depressed, sad, exhausted, and happy. We also assessed changes in hypoglycemia, panic, euphoria, illusions, headaches, bleeding, eye function, diarrhea, body pains, sexual desire, and sleep quality. We assessed adherence to diet by a validated food frequency questionnaire (35) and used a validated questionnaire to assess physical activity (36) .
Laboratory Blood Biomarker Methods
Blood samples were obtained by venipuncture at 8 a.m. after an 8-hour fast at baseline and at 6 and 24 months; samples were stored at Ϫ80°C. Measurements were performed in laboratories in Leipzig, Germany. Fasting plasma glucose level was measured by Roche Glucose Hexokinase, generation 3 (Roche). 
Sensitivity Analyses to Evaluate Departures From the Assumption That Data Were Missing at Random
Among the participants who dropped out of the study, baseline characteristics were similar across their assigned intervention groups in demographics, clinical presentation, blood biomarkers, and the use of medications. Comparing those who dropped out with those who completed the study, baseline characteristics in demographics, clinical presentation, blood biomarkers, and the use of medications were similar except that those who dropped out had higher baseline HOMA-IR scores than those who completed the study.
Within each intervention group, baseline characteristics in demographic, clinical presentation, blood biomarkers, and the use of medications were similar between those who dropped out versus completed the study with the exception of the white wine group, in which those who dropped out were younger, had lower baseline HDL-C levels, and used fewer oral glycemic medications than those who completed the study. Bars indicate 95% CIs, and the P value denotes comparison of 2-y differences in the red wine group versus the water group.
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